Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zinc sulfate + Toripalimab + Axitinib vs Toripalimab + Axitinib in advanced renal cell carcinoma
ChiCTR2600130070Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in renal cell carcinoma (RCC) comparing Toripalimab + axitinib + zinc sulfate with Toripalimab + axitinib (2 arms). Primary endpoints: Progression-free survival (PFS) and Serum zinc concentration during zinc supplementation. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
toripalimabaxitinibzinc
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2600130070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130070.